SCHEMBL4975289

SCHEMBL4975289

COc1ccc2c(c1)CCC(=CC(=O)O)C2=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 7/20 0.65
CYP26A1 O43174 3/20 0.62
SMN1; SMN2 Q16637 5/20 0.60
ALDH1A1 P00352 4/20 0.60
MAPT P10636 4/20 0.60
LMNA P02545 3/20 0.60
KDM4E B2RXH2 3/20 0.60
GAA P10253 1/20 0.60
HTT P42858 1/20 0.60
CYP19A1 P11511 1/20 0.59
MAPK1 P28482 1/20 0.57
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
CYP27A1 Q02318 2/20 0.56
HPGD P15428 2/20 0.56
ABCB1 P08183 2/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14061927 1.00 MIF (0.65) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL14137061 1.00 MIF (0.65) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3018271 0.91 MIF (0.57) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL9391395 0.91 MIF (0.57) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3018274 0.91 MIF (0.57) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL11458794 0.87 MIF (0.61) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL12760787 0.84 MIF (0.67) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL6361514 0.84 MIF (0.67) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3450462 0.83 CYP19A1 (0.56) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3450465 0.83 CYP19A1 (0.56) MIFCYP26A1SMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2916839-B1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-10-11 EP disclosed
US-9624174-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE LLC (US) 2017-04-18 US disclosed
US-20160068487-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC 2016-03-10 US disclosed
EP-2723332-B1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-03-02 EP disclosed
US-9242929-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-26 US disclosed
US-9221766-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE LLC (US) 2015-12-29 US disclosed
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) 2015-10-29 US disclosed
EP-2916839-A2 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Glaxosmithkline LLC (US) 2015-09-16 EP disclosed
WO-2014074761-A2 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-05-15 WO disclosed
EP-2723332-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-04-30 EP disclosed
WO-2012162127-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-11-29 WO disclosed
EP-1270545-B1 PROCESS FOR PRODUCING AMINE DERIVATIVES TAKEDA PHARMACEUTICAL (JP) 2008-11-05 EP disclosed
US-6784314-B2 HAVING THE ACTION OF INHIBITING THE SECRETION AND ACCUMULATION OF AMYLOID BETA PROTEIN TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-08-31 US disclosed
US-20030139602-A1 Process for producing amine derivatives TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2003-07-24 US disclosed
EP-1270545-A1 PROCESS FOR PRODUCING AMINE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors DGAT1, DGAT2, LCAT MIF 3756/4885CYP26A1 861/4885SMN1; SMN2 4859/4885
US-20030139602-A1 Process for producing amine derivatives APP, BACE1, IAPP MIF 4290/4885CYP26A1 2578/4885SMN1; SMN2 1882/4885
US-20160068487-A1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, LCAT MIF 3495/4885CYP26A1 508/4885SMN1; SMN2 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.